Clinical Outcome of Neonates With GBS Positive Culture-12 Year Retrospective Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00326313|
Recruitment Status : Unknown
Verified May 2006 by Sheba Medical Center.
Recruitment status was: Not yet recruiting
First Posted : May 16, 2006
Last Update Posted : May 16, 2006
Streptococci group B (GBS) is a the major reason for morbidity and mortality in neonates. It can present as pneumonia ,meningitis or sepsis.The mortality today is 5-20% and even more in preterm babies.
During the past two decade, the introduction of protocols for prophylactic antibiotics for women with a high risk for GBS infection, have led to a decline of 65% in GBS cases(0.32 for 1000 live birth compared to 1.8 cases in 1000).The purpose of the study is to check the morbidity and mortality at Sheba medical center in the last 12 years in children with positive blood culture for GBS. We assume that in our hospital the morbidity and mortality is less then expected. If proven right, we would then check the reasons for that outcome considering the type and length of treatment and the different virulence of the streptococcus.
|Condition or disease|
|Infants With Positive GBS Bacteremia|
|Study Type :||Observational|
|Estimated Enrollment :||74 participants|
|Official Title:||Clinical Outcome of Neonate With GBS Positive Culture-12 Year Retrospective Study|
|Study Start Date :||June 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00326313
|Principal Investigator:||Tzipora Strauss, MD||Sheba Medical Center|